The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
CEO David King said that the acquisition of Sequenom positions LabCorp as a leader in NIPT, women's health, and reproductive genetics.
The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.
The $302 million deal, which was expected to close by the end of the year, passed US government antitrust review in August.
The deal is still subject to other closing requirements including meeting a minimum tender condition.
Sequenom, which will be acquired by LabCorp this year, saw an increase in testing for average-risk pregnancies in the quarter, despite lower overall revenues.
A month after Brexit fears pushed the GenomeWeb Index down half a percent, companies rallied on news of an acquisition and better than expected Q2 performances.
The firm, as indicated by its agreement to acquire Sequenom, is optimistic about the prospects for NIPT.
LabCorp plans to acquire all of Sequenom's outstanding stock for $2.40 per share.
During a case management conference last week, Premaitha said the EC's competition department contacted it regarding an investigation into Illumina and Sequenom.
Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.
Bill Gates tells the Telegraph that bioterrorism is a serious risk.
The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.
CBS News reports that the White House Science Fair is to continue under President Donald Trump.